Skip to Content


In the US, Onglyza (saxagliptin systemic) is a member of the drug class dipeptidyl peptidase 4 inhibitors and is used to treat Diabetes, Type 2.

US matches:

UK matches:

Ingredient matches for Onglyza


Saxagliptin is reported as an ingredient of Onglyza in the following countries:

  • Australia
  • China
  • Colombia
  • Egypt
  • Greece
  • Indonesia
  • Italy
  • Japan
  • Lebanon
  • Norway
  • Philippines
  • Poland
  • Thailand
  • Tunisia
  • Turkey
  • United States
  • Vietnam

Saxagliptin hydrochloride (a derivative of Saxagliptin) is reported as an ingredient of Onglyza in the following countries:

  • Argentina
  • Austria
  • Belgium
  • Canada
  • Chile
  • Croatia (Hrvatska)
  • Czech Republic
  • Denmark
  • Finland
  • France
  • Germany
  • Hong Kong
  • Hungary
  • Ireland
  • Israel
  • Latvia
  • Lithuania
  • Malaysia
  • Mexico
  • Netherlands
  • Portugal
  • Romania
  • Singapore
  • Slovenia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Taiwan
  • United Kingdom

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.